Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: STARLIX

« Back to Dashboard

Summary for Tradename: STARLIX

Patents:4
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: STARLIX

Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists

Clinical Trials for: STARLIX

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Status: Completed Condition: Diabetes Mellitus, Type 2

Study of the Durability of Glycemic Control With Nateglinide
Status: Recruiting Condition: Type 2 Diabetes Mellitus

Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
Status: Completed Condition: Diabetes Mellitus, Type 2

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition
Status: Completed Condition: Healthy

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
Status: Completed Condition: Healthy

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
Status: Completed Condition: Diabetes Mellitus, Type 2

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
Status: Completed Condition: Type 2 Diabetes Mellitus

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients
Status: Completed Condition: Renal Transplant Recipients; Posttransplant Diabetes Mellitus; Posttransplant Impaired Glucose Tolerance

A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
Status: Completed Condition: Diabetes Mellitus, Type 2

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects
Status: Completed Condition: Healthy Volunteers

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXNo6,559,188<disabled>Y<disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXYes6,844,008<disabled>Y<disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXYes6,559,188<disabled>Y<disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXNo6,844,008<disabled>Y<disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXYes6,641,841<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: STARLIX

Drugname Dosage Strength RLD Submissiondate
nateglinideTablets60 mg and 120 mgStarlix12/22/2004
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc